

## WHO COVID-19 Vaccines Research Forum

6 April 2021

14:00 – 16:45 Central European Time CET

Agenda



## COVID 19 Vaccine R&D Research Forum



## Objectives of the monthly forum

The goals of these regular meetings are:

- o To provide rapid updates of COVID-19 vaccine research progress against WHO R&D Blueprint roadmap priorities with the ability to pivot given dynamic research needs.
- o To encourage and facilitate the rapid dissemination and open discussion of research protocols and emerging results.

## Chairperson – Philip Krause

Time	Topic	Speakers
14:00 – 14:05	Welcome remarks and outlining objectives of the monthly calls	Philip Krause
What's new?	Updates from WHO Working Groups	
14:05 – 14:20	WHO Decision framework for assessing the impact of SARS-CoV-2 Variants of Concern on public health interventions	Sylvie Briand
14:20 – 14:35	Assays: updates from the last month	David Montefiori on behalf of the WHO Working Group
14:35 – 14:50	Animal Models and variants: what is next?	Martin Beer on behalf of the WHO Working Group
14:50 – 15:05	Hybrid study designs: can they help address the perceived challenges of randomized trials today?	Thomas Fleming
15:05 – 15:20	Sieve analysis and their relevance for randomized and non-randomised trials	Ira Longini
15:20 – 15:35	Regulatory convergence: updates	Rogerio Gaspar/David Wood
15:35 – 15:45	Hot questions from the audience (3 questions selected by the Chairperson)	Plenary
Vaccine developers' corner: Current research plans (including related to variants)		
15:45 – 16:15	Open to developers to share any plans or critical findings (5 minutes each)	Scot Roberts (Altimmune) Guido Grandi (University of Trento) Jeff Wolf (Heat Biologics) Thomas Monath (Vaxxinity) Randy Hyer (Moderna)
What's new? Updates from the partners		
16:15 – 16:35	Critical updates from the partners	CEPI: Kristine Rose GLOPID-R: Hans Hagen NIH: Mary Marovich
16:35 - 16:45	Main take home messages	Philip Krause
16:45	End of meeting	